Mads Israelsen
YOU?
Author Swipe
View article: PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis
PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis Open
View article: Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial
Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial Open
View article: PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study
PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study Open
View article: Editorial: Implementing Risk Assessment Tools for <scp>MetALD</scp> in Clinical Practice—Authors' Reply
Editorial: Implementing Risk Assessment Tools for <span>MetALD</span> in Clinical Practice—Authors' Reply Open
View article: <scp>M</scp> et <scp>ALD</scp> : Diagnosis and Prognosis With Non‐Invasive Tests
<span>M</span> et <span>ALD</span> : Diagnosis and Prognosis With Non‐Invasive Tests Open
Background Non‐invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline‐recommended NIT cut‐offs apply to metabolic and alcohol‐related liver disea…
View article: Phosphatidylethanol in steatotic liver disease
Phosphatidylethanol in steatotic liver disease Open
Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and their combination (MetALD). Distinguishing these subclasses relies on accurately assessing…
View article: Alcohol-related liver disease disrupts bile acid synthesis and is associated with compensatory gut microbiota changes
Alcohol-related liver disease disrupts bile acid synthesis and is associated with compensatory gut microbiota changes Open
Background Alcohol overuse disrupts liver function and alters microbial gut communities, with alcohol-related liver disease (ALD) accounting for half of all liver-related deaths worldwide. Bile acids (BAs) regulate liver and gut function, …
View article: Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community Open
GOV: NCT03308916.
View article: The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial
The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial Open
Impaired gut barrier function may lead to progression of liver fibrosis in people with alcohol-related liver disease. The postbiotic ReFerm® can lower gut barrier permeability and may thereby reduce fibrosis formation. Here, we report the …
View article: Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE
Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE Open
EudraCT number: 2014-002,300-24 and International Standard RCT Number: 14,174,793 Research Ethics Committee Number: 15/LO/0104.
View article: Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments
Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments Open
SLD and the subclassification hereof is highly dynamic, especially driven by changes in alcohol use and hepatic steatosis. This affects eligibility for clinical trials and clinical management of patients with SLD.
View article: Microbiome testing in Europe: navigating analytical, ethical and regulatory challenges
Microbiome testing in Europe: navigating analytical, ethical and regulatory challenges Open
Recommendations or actions, specific to the context of use of microbiome testing kits, are listed to improve the quality and the robustness of these test kits to meet expectations of end users (consumers, patients and healthcare profession…
View article: Author Correction: Examining the healthy human microbiome concept
Author Correction: Examining the healthy human microbiome concept Open
View article: Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations
Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations Open
The microbiota in individual habitats differ in both relative composition and absolute abundance. While sequencing approaches determine the relative abundances of taxa and genes, they do not provide information on their absolute abundances…
View article: Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists Open
Chronic liver disease is a major cause of mortality, with approximately 2 million deaths worldwide each year, and it poses a significant economic burden. The most common cause of chronic liver disease in the United States and Europe is ste…
View article: State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus
State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus Open
Although microbiome signatures have been identified in various contexts (ie, pathogenesis of non-communicable diseases and treatment response), qualified microbiome-based biomarkers are currently not in use in clinical practice. The Human …
View article: Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake
Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake Open
View article: Plasma cathepsin D as an early indicator of alcohol-related liver disease
Plasma cathepsin D as an early indicator of alcohol-related liver disease Open
Alcohol-related liver disease is the leading cause of liver disease-related morbidity and mortality worldwide. However, the currently available non-invasive methods to diagnose MetALD/ALD are only able to detect advanced stages of MetALD/A…
View article: Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases Open
The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitorin…
View article: Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations
Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations Open
The microbiota in individual habitats differ both in relative composition and absolute abundance. While sequencing approaches determine only the relative abundances of taxa and genes, experimental techniques for absolute abundance determin…
View article: Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease Open
Patients at risk of alcohol-related liver disease (ALD) are at significant risk of progressive disease and adverse outcomes. Monitoring is essential for optimal disease surveillance and patient guidance, but non-invasive monitoring tools a…
View article: Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial Open
Introduction Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare systems. A precision medicine a…
View article: Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease
Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease Open
This study reveals that infections significantly worsen the prognosis of patients with early alcohol-related liver disease (ALD), increasing the likelihood of decompensation and death by up to eight times. These findings, pertinent to heal…
View article: LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score
LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score Open
View article: Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals Open
Screening for liver fibrosis is associated with sustained improvements in alcohol consumption, diet, weight, and exercise in at-risk ALD and MASLD. The changes are most pronounced in screening positive participants but not limited to this …
View article: Noninvasive assessment of hepatic decompensation
Noninvasive assessment of hepatic decompensation Open
Noninvasive tests (NITs) are used in all aspects of liver disease management. Their most prominent break-through since the millennium has been in advancing early detection of liver fibrosis, but their use is not limited to this. In contras…
View article: Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation‐related markers
Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation‐related markers Open
Background Frequent binge drinking is a known contributor to alcohol‐related harm, but its impact on systemic and hepatic inflammation is not fully understood. We hypothesize that changes in immune markers play a central role in adverse ef…
View article: Validation of scores of <scp>PRO‐C3</scp> to predict liver‐related events in alcohol‐related liver disease
Validation of scores of <span>PRO‐C3</span> to predict liver‐related events in alcohol‐related liver disease Open
Background and Aims Risk prediction in alcohol‐related liver disease (ArLD) is an unmet need. We aimed to assess PRO‐C3 models to predict liver‐related events (LRE) in patients with a history of excessive alcohol use without an established…
View article: Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease Open
Clinicaltrials.gov number NCT03308916.
View article: Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial Open
The EU Horizon 2020 Research and Innovation Program and The Novo Nordisk Foundation.